India’s Ayush Ministry integrates Ayurveda via the National Ayush Mission and 12,500 Ayush Health and Wellness Centres by 2023–24.

WHO established its Global Centre for Traditional Medicine in India to build a reliable evidence base using AI and big data.

An IIT Delhi trial found Ayurveda plus personalized yoga improved symptoms in over 50% of 30 high‑risk COVID‑19 patients within five days, with 90% recovered by days 9–10.

Neem bark extract shows antiviral activity and can bind the SARS‑CoV‑2 spike protein.

Indian teams are studying Rhododendron arboreum for antiviral activity with promising early results.

A UK trial is testing Ashwagandha for Long Covid in 2,000 people, funded by India’s Ministry of Ayush.

About 400 medicinal plants show antidiabetic activity, including 21 with prominent effects.

The polyherbal BGR‑34 lowers blood sugar and addresses obesity in type‑2 diabetes.

Turmeric is under study to help maintain blood sugar in type 2 diabetes.

Madhavbaug delivers evidence‑based Ayurveda therapies for cardiac ailments via virtual clinics, telemedicine, and digital partnerships.

AYUSH QOL2C targets quality‑of‑life improvement for cancer patients through Ayurveda‑based adjuncts.

Dr BRKR Government Ayurvedic Medical College is studying Ayurvedic management of mucormycosis.

Institutions include the All India Institute of Ayurveda, National Institute of Unani Medicine, and Central Research Institute of Yoga & Naturopathy.

A 100‑bed Yoga and Naturopathy hospital is planned at Dihing Khamtighat.

Amrita Center and the National Medicinal Plant Board map and research medicinal plant resources.

India has a regulatory pathway for phytopharmaceuticals requiring evidence of quality, safety, and efficacy.

The Ayush Ministry warns manufacturers against misleading claims and enforces labeling and advertising norms.

Quality reforms include revised GMP, risk‑based inspections, and a digital regulatory ecosystem.

The government funded stronger drug regulation to reduce substandard medicines.

India’s Ayush Ministry integrates Ayurveda via the National Ayush Mission and 12,500 Ayush Health and Wellness Centres by 2023–24.

Title:

Content: you are here: HomeNewsIndia

Govt working towards scientifically integrating traditional and modern medicine: Sonowal

The ministry is working on operationalisation of 12,500 Ayush health and wellness centres through the support of state and Union territory governments under the National Ayush Mission (NAM) by 2023-24, Sonowal said.

September 07, 2023 / 12:48 AM IST

Ayurveda representational image

India's rich heritage of traditional form of medicine has withstood the test of time and the government has been working towards scientifically integrating it with modern medicine, Union Ayush Minister Sarbananda Sonowal said on Wednesday.

The Regional Review meeting of National Ayush Mission was ceremonially inaugurated by him along with his deputy Munjpara Mahendrabhai.

During the meeting, representatives of all participating states and Union territories presented detailed presentations on the state of Ayush and progress of leading Ayush programmes under implementation.

Speaking on the occasion, Sonowal said, "Our rich heritage and potential of traditional form of medicine has withstood the test of time in generations of humanity to live a better, healthier and happier life. We must take full advantage of this generous forms of medicine - be it Ayurveda, Siddha, Unani, Yoga, Naturopathy, Sowa Rigpa, or Homoeopathy."

He also said that under the visionary leadership of Prime Minister Narendra Modi, the government has been working towards scientifically integrating traditional forms of medicine with the modern medicine.

Highlighting the utility of Ayush system of medicine, he further said that it has some robust programmes like Ayurvidya for promotion of healthy lifestyle through Ayush for school children, Supraja for maternal and neonatal intervention, Vayomitra for geriatric issues; prevention and management of Osteoarthritis and other musculo-skeletal disorders, and Ayush mobile medical units.

The ministry is working on operationalisation of 12,500 Ayush health and wellness centres through the support of state and Union territory governments under the National Ayush Mission (NAM) by 2023-24, Sonowal said.

The ministry of Ayush has so far released Rs 719.70 crore to southern states and Union territories - Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu and Telangana - under NAM since 2014-15, he said, adding it has also supported 17 Integrated Ayush hospitals in the southern states and out of that six are operational as reported by them.

Mahendrabhai stressed on the need to emphasise on outcomes as a more meaningful measure of programme value than output.

"We may have to realign our strategies and techniques to plan, execute and report our performance that facilitates measure of outcomes," the minister of state for Ayush said.

NAM is being implemented with the vision and objectives to provide Ayush health care services throughout the country by strengthening and improving facilities, to provide informed choice to the needy public.

PTI
first published: Sep 7, 2023 12:47 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

WHO established its Global Centre for Traditional Medicine in India to build a reliable evidence base using AI and big data.

Title:

Content: WHO holds first summit on traditional medicine
Cairo - Center Gate Thursday 17 August 2023, 11: 39 am
The World Health Organization (WHO) on Thursday opened its first summit on traditional medicine, amid the United Nations body ’ s stated quest to gather evidence and data to allow the safe use of such treatments.
Traditional medicines are “the first refuge of millions of people around the world, ” the WHO said, with a summit in India bringing together policymakers and academics to“ mobilize political commitment and encourage evidence-based action ” on these treatments.
WHO President Tedros Adhanom Ghebreyesus said: “WHO is working to gather evidence and data to guide policies, standards and norms for the safe, fair and cost-effective use of traditional medicine. ”
The two-day World Health Organization (WHO) World Summit on Traditional Medicine is being held in conjunction with the G20 Health Ministers ’ Meeting in Gandhinagar, India.
The summit is set to be a regular event, following the opening last year of the World Health Organization ’ s World Centre for Traditional Medicine in the Indian state of Gujarat.
Criticism of traditional medicines
While traditional medicines are widely used in some parts of the world, they also face severe criticism.
The United Nations Health Agency defines traditional medicine as the knowledge, skills and practices used over time to maintain health and to prevent, diagnose and treat physical and mental illnesses.
But many traditional treatments lack any proven scientific value, and conservation activists say the industry is pushing for increased trade in endangered animals, including tigers, rhinos and squam-eaters, and threatening the survival of entire species.
Vietnam discovers 2,000 dead cats dedicated to traditional medicine
Chinese Prefer Traditional Medicine Against Coronavirus
Traditional medicine against Corona.
Who's the winner?
The use of home remedies during the pandemic to treat Covid-infected people increased, including a green wormwood herbal drink promoted by the President of Madagascar as a treatment.
The plant has been shown to be effective in treating malaria, but its use to combat COVID-19 has been widely scorned by many doctors.
In China, traditional medicine has a long history, but major European medical bodies have previously requested that it be subject to the same principles of regulatory oversight as traditional medical methods.
John Ryder, head of research at the World Health Organization, said: “Scientific progress in traditional medicine must be subject to the same rigorous standards as in other areas of health. ”
The use of traditional medicine in the absence of rules
Of the 194 WHO member states, 170 have recognized their use of traditional and complementary medicine since 2018, but only 124 have reported laws or rules for the use of herbal medicines, while only half have a national policy on such methods and medicines.
According to the World Health Organization (WHO), “natural treatment does not always mean it is safe, and centuries of use are not a guarantee of effectiveness; therefore, the scientific and practical method must be applied to provide the accurate evidence required. ”
About 40% of approved pharmaceutical products currently in use are derived from a “natural product basis, ” according to the World Health Organization, which cites“ prominent drugs ” derived from traditional medicine, including aspirin, based on formulations using willow bark.
More from the middle gate.
Related Titles
Washington Condemns Russian Attacks on Ukrainian Infrastructure Facilities in...
Zelensky: First cargo ship to sail through Black Sea ‘ important step ’
Canada's northernmost city ordered to evacuate as fires widen
Ukrainian Foreign Minister: We seek to strengthen our relations with Africa
Ukrainian Foreign Minister: We want to liberate our entire territory, no matter how long it takes
More...
Most preferred in this section.

What is the World Health Organization doing to promote traditional medicine, including Ayurveda?

Gathering evidence and data to guide policies

An IIT Delhi trial found Ayurveda plus personalized yoga improved symptoms in over 50% of 30 high‑risk COVID‑19 patients within five days, with 90% recovered by days 9–10.

Title:

Content: Home » News » education-career » Yoga, Ayurveda Could be Effective in Treating High-Risk Covid-19 Cases, Claims IIT-Delhi Research

Yoga, Ayurveda Could be Effective in Treating High-Risk Covid-19 Cases, Claims IIT-Delhi Research

By: Education and Careers Desk

News18.com

Last Updated: September 13, 2022, 16:36 IST

New Delhi, India

The researchers claimed that that high-risk COVID-19 patients undergo severe anxiety, which may further deteriorate their condition (File Photo)

IIT Delhi researchers suggest that in addition to the treatment for COVID-19, Yoga and Ayurveda maybe instrumental in relieving such patients from anxiety and aid in speedy post-treatment recovery

Advertisement

Yoga and Ayurveda maybe effective in the treatment of high-risk cases of COVID-19, suggests a research study by IIT Delhi on successful treatment of 30 high-risk COVID-19 patients. This study was conducted by a team of researchers at IIT Delhi and Dev Sanskriti Vishwavidyalaya, Haridwar.

The researchers claimed that that high-risk COVID-19 patients undergo severe anxiety, which may further deteriorate their condition. They further suggest that in addition to the treatment for COVID-19, Yoga and Ayurveda maybe instrumental in relieving such patients from anxiety and aid in speedy post-treatment recovery.

Also read| IIT Delhi Launches App to Prevent Bengaluru Floods Like Situation, to Predict Waterlogging

The findings of the study have appeared in the Indian Journal of Traditional Knowledge. The research team consists of Dr Sumitra A Bentur, Private practitioner, Greater Noida (West), Uttar Pradesh, Dr Alka Mishra, Dev Sanskriti Vishwavidyalaya, Haridwar, Uttarakhand; Dr Yogish Kumar, Advait Clinic, Delhi, Dr Sonika Thakral, IIT Delhi, Sanjiv, IIT Delhi and Shaheed Sukhdev College of Business Studies, University of Delhi, Prof Rahul Garg, IIT Delhi.

RELATED NEWS

As per the institute, the patients were prescribed Ayurvedic medicines through telemedicine, and administered a personalized therapeutic yoga programme using video conferencing. Almost all the patients were classified as high-risk owing to one or more of co-morbidities such as diabetes mellitus, hypertension, chronic kidney disease, coronary artery disease (which are known to lead to severe outcomes in cases of COVID-19), and/or age above 60, said IIT Delhi.

“The treatment given to the patients was personalized (in accordance with the classical texts) and took account of each patient’s medical history and the symptoms presented, which made it more effective as compared to a fixed standardized treatment plan," said the IIT.

The treatment included ayurvedic medicines, daily yoga-sessions including deep relaxation techniques, pranayama and basic asanas and some lifestyle modifications. Based on the administered treatment, the cases were categorized into YAS (Yoga-Ayurveda based treatment, with possibly allopathic supplements: 4 patients), YASP (Yoga-Ayurveda based treatment, with possibly allopathic supplements and paracetamol: 6 patients), YAM (Yoga-Ayurveda based treatment, and Modern Western Medicine (MWM), that is, allopathy as adjunct: 6 patients), MYA (first tried MWM, later switched to Yoga-Ayurveda: 14 patients). added the institute.

The patients, most of whom presented with many symptoms prior to the yoga and Ayurveda treatment, were followed-up telephonically regularly until recovery. More than half of symptomatic patients started improving within 5 days (90 per cent within 9 days), more than 60 per cent reported at least 90 per cent recovery within 10 days, added IIT Delhi.

Six patients with oxygen saturation (SpO2) below 95 per cent, benefited through Makarasana and Shithilasana; none progressed to composite endpoints (consisting of admission to Intensive Care Unit, invasive ventilation or death). Considering that approximately 19.3 per cent of the patients with these comorbidities progress to composite end points, the p-value was found to be 7.21 x 10−3.

“The study also demonstrates an urgent need to scientifically examine the Traditional Indian Knowledge systems at the top academic institutions. A timely and suitably designed randomized controlled trial evaluating the efficacy of Ayurveda and Yoga based personalized integrative treatment for COVID-19 would have equipped the people with much more credible and dependable information about their use in managing COVID-19" said Prof Rahul Garg, IIT Delhi, who conceptualized the project.

“Most patients reported that the therapy had a profound impact on their recovery process, with many experiencing improvements with respect to their comorbidities too. By the end of the treatment, several patients had decided to adopt Yoga in their lifestyle, and several turned to the Ayurveda doctors in the team for management/treatment of their comorbidities", said Dr Sonika Thakral who coordinated with the patients for routine follow-up.

“On the whole, the belief of the patients in the efficacy of these traditional systems of medicine was extremely enhanced," said Dr Alka Mishra who administered Ayurveda treatment to some patients. “We are observing an increasing trend towards ancient systems of medicine", said Dr Yogesh Kumar who also administered Ayurveda treatment to some patients.

“The said interventions are believed to have collectively accelerated the recovery process by checking anxiety, instilling peace of mind and enhancing the overall well-being of the patients," said Dr Sumitra A Bentur, private practitioner, who designed the Yoga intervention and conducted Yoga sessions for some of the patients.

Read all the Latest Education News and Breaking News here

Follow us on

About the Author

Education and Careers DeskA team of reporters, writers and editors brings you news, analyses and informati...Read More

first published: September 13, 2022, 16:30 IST
last updated: September 13, 2022, 16:36 IST

What is the traditional Indian medical system called?

Neem bark extract shows antiviral activity and can bind the SARS‑CoV‑2 spike protein.

Title:

Content: Neem tree extract may help treat, cut spread of COVID-19: Study

PTI | New Delhi | Updated: 01-03-2022 15:22 IST | Created: 01-03-2022 15:08 IST
  • Country:
  • India

Extract from the bark of the Neem tree may help treat and reduce the spread of SARS-CoV-2, the virus that causes COVID-19, according to a study led by researchers at the Indian Institute of Science Education and Research (IISER) Kolkata.

The Neem tree, indigenous to India, has been used for thousands of years for its anti-parasitic, anti-bacterial and antiviral properties, the researchers said.

The bark extract has helped treat malaria, stomach and intestinal ulcers, skin diseases and many other diseases, they said. The latest study, published recently in the journal Virology, shows that components of Neem bark may target a wide range of viral proteins, suggesting its potential as an antiviral agent against emerging variants of coronaviruses, including SARS-CoV-2.

''The goal of this research is to develop a Neem-based medication that can reduce the risk of serious illness when someone is infected with coronaviruses,'' said study co-author Maria Nagel, a professor at the University of Colorado School of Medicine, US.

''We hope that scientists won't have to continuously develop new therapies every time a new SARS-CoV-2 variant emerges,'' she said.

Just like how people take penicillin for strep throat, the researchers envision taking the Neem-based drug for COVID-19, allowing them to resume their normal lives without fear of hospitalisation and death.

The scientists investigated the impact of the bark extract against coronaviruses in their laboratories.

Researchers at IISER Kolkata tested the extract in animal models and showed that it had antiviral properties against coronavirus.

Using computer modelling, the researchers predicted that Neem bark extract will bind to the SARS-CoV-2 spike protein at various locations, preventing virus entry to host cells.

The spike protein is used by the SARS-CoV-2 virus to enter and infect cells.

Nagel's lab at the University of Colorado tested the Neem bark extract in SARS-CoV-2 human lung cells.

The extract proved as effective as a preventive drug for infection and also decreased virus replication and spread after infection.

''The next step in our research is to identify the specific components in Neem bark extract that are antiviral. Because these components bind to various regions of SARS-CoV-2, we believe that it will be effective on emerging variants with spike mutations,'' said Nagel.

''We will then determine the formulation of dosage for an antiviral drug to treat coronavirus infections,'' she said.

The findings could guide new antiviral therapeutic efforts to combat the ongoing pandemic, while holding out the promise for treating new coronavirus strains, the researchers added.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback

Indian teams are studying Rhododendron arboreum for antiviral activity with promising early results.

Title:

Content: 00: 00
Expo 2020 Dubai Today
Indian study: Himalayan plant promising in treatment of COVID-19 infection
T + T - normal size
In addition to regular vaccinations recommended to combat the novel coronavirus COVID-19, scientists around the world are researching drugs to protect the body from viral infections, and a team of researchers from India at the Indian Institute of Technology (IIT) and other scientists are now finding hope in the petals of a Himalayan plant that they believe could be used to treat COVID-19.
Dr Shyam Kumar Masakaballi, associate professor of the study, said: “Among the therapeutic agents being studied, plant-derived chemicals are a particularly promising area due to their synergistic activity and natural source with few toxicity problems. ”
The team found that the petals of the Himalayan plant, called rosebush or rhododendron arboreum, are consumed by locals for their various health benefits.
Scientists are embarking on scientific tests of extracts containing various phytochemicals, with a particular focus on antiviral activity, to find that Himalayan plants are a promising candidate against COVID-19, with the results published in the journal Polymolecular Structures and Dynamics, "confirming that their results support the urgent need for further scientific studies in this area.
Print Email

A UK trial is testing Ashwagandha for Long Covid in 2,000 people, funded by India’s Ministry of Ayush.

Title:

Content: Tuesday 10 August 2021 1:10 pm

Long Covid cure? Researchers to trial traditional Indian herb treatment

The London School of Hygiene & Tropical Medicine will work with the All India Institute of Ayurveda to determine whether a traditional Indian herb can help people recover from long Covid.

Ashwagandha, commonly known as Indian winter cherry, is traditionally used in the Indian Ayurvedic system of medicine to boost energy, reduce stress and strengthen the immune system.

Experts said recent trials had proven the herb’s efficacy in reducing anxiety, stress, improving muscle strength and reducing fatigue symptoms in patients with chronic diseases.

Long Covid patients can suffer from cognitive dysfunction, poor mental health, extreme fatigue and muscle weakness.

It is estimated these symptoms affect 10 to 20 per cent of Covid survivors and can last for one to three months or longer in many cases.

The study, funded by the Ministry of Ayush of the Government of India, will include a double-blind clinical trial involving 2,000 people living in the UK with long Covid.

Half of the trial participants will take 500mg Ashwagandha tablets twice a day for three months, while the other half will be given a placebo.

Researchers will randomly select participants to have a monthly follow-up of self-reported quality of life, impairment to activities of daily living, mental and physical health symptoms, supplement use and adverse events.

The study is expected to last for over a year.

“Ashwagandha has been shown to reduce symptoms of other conditions that are similar to those of long Covid, so we are hopeful that it will be an effective way to combat the condition,” said Sanjay Kinra, professor in clinical epidemiology at the London School of Hygiene & Tropical Medicine.

The research is also supported by the UK’s All-Party Parliamentary Group on Indian Traditional Sciences and the Traditional Complementary and Integrative Medicine Unit at the World Health Organisation (WHO).

Research is the only way to ensure appropriate integration of traditional medicine knowledge into mainstream medical practice,” said technical officer at WHO Geneva, Geetha Krishnan, who helped to facilitate the research project.

Share

About 400 medicinal plants show antidiabetic activity, including 21 with prominent effects.

Title:

Content: Nation

Researchers claim 400 medicinal plants have anti-diabetic properties

X

New Delhi: As a part of its initiatives to reduce the diabetic burden, the scientists have emphasised on exploring the anti-diabetic properties of around 400 medicinal plants to be used in making medicines based on ayurvedic formulations to control type-2 diabetes by reducing sugar level in blood.

According to the researchers from Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry and All India Institute of Medical Sciences, Kalyani, as of now, there are 21 herbal plants, including Vijayasar, Jamun, Cumin, Daruharidra, little gourd, bael, fenugreek, neem, amla, turmeric that have been found to have prominent anti-hyperglycemic action.

Stressing that diabetes cure lies in the nature, the researchers asserted that intensive studies have been done on 21 herbs and in-depth research on at least 400 herbal plants is needed to exhibit their anti-diabetic properties..

As per their research paper, which is published in the World Journal of Diabetes, these medicinal plants have been the basis of many drugs to manage diabetes. The researchers have also cited the example of BGR-34, a herbal formulation developed by the

Council of Scientific and Industrial Research (CSIR), which has been used to manage diabetes.

The herbal drug BGR-34 contains not one, but many active compounds derived from four medicinal herbs daruharidra, gudmar, methi and vijayasar. Apart from this, giloe and majeeth have also been added to increase immunity as well as antioxidants levels, said Dr Sanchit Sharma, executive director, AIMIL Pharmaceuticals.

The study titled “Treatment on Nature’s lap: Use of Herbal Products in the Management of Hyperglycemia” stated

that although partial research conducted on eight plants, including pomegranate, shilajit, bean, tea, ginkgo biloba, and saffron demonstrate anti-diabetic properties,

it emphasised the need for further trials.

A recent study conducted by AIIMS Delhi revealed that BGR-34, an Ayurvedic medicine, not only helps in reducing sugar levels but also addresses obesity.

The researchers also noted that several allopathic drugs used in diabetes management have their origins in herbal remedies.

For instance, metformin, a widely prescribed medication, is derived from the Galega officinalis plant, which

was historically used to treat diabetes in 19th century Europe.

Next Story

In what areas have the medical uses of traditional Indian medicine been studied?

The polyherbal BGR‑34 lowers blood sugar and addresses obesity in type‑2 diabetes.

In what areas have the medical uses of traditional Indian medicine been studied?

Turmeric is under study to help maintain blood sugar in type 2 diabetes.

Title:

Content: News

Take up pilot project on Ayurveda treatment: MLA Ramdas

August 29, 2022

Mysore/Mysuru: Studies conducted across the world have found that several traditional medicines commonly used in India as part of Ayurveda are effective in maintaining blood sugar levels in patients with Type 2 diabetes.

Ayurveda is a traditional medical system that has been used for thousands of years in India and some of the herbs included are also used in other parts of the world. In this direction, a systematic project must be developed to treat diabetes, suggested MLA S.A. Ramdas. The suggestion was accepted by Ayurveda practitioners and experts in the field.

The MLA was speaking after inaugurating a free Ayurvedic treatment camp organised at the Sri Ganapathy Ashram on Nanjangud Road yesterday. The camp was organised inside the auditorium of Lakshminarasimha Kuteera of the Ashram by the Government Ayurvedic Research Centre and Ayurveda Academy of Chamarajpet in Bengaluru.

Ramdas suggested the doctors and officers launch a pilot project in a particular locality or a Ward and assured of making all facilities on behalf of the Government. He said that the project can be taken up on Sept. 17, the birthday of Prime Minister Narendra Modi for one year to achieve tangible results for the target population, he suggested.

Modern diabetes drugs are known for side effects and toxicity while Ayurveda works by controlling blood sugar and limiting the harmful effects of other drugs. Turmeric, for example, has been used for the treatment of diabetes in Ayurveda and traditional Chinese medicine, he added.

He said new Ayurvedic remedies were still in great demand for treating diabetes because of the limited efficacy and undesirable side effects of current drugs. A multi-pronged and individualised approach must be used to manage health conditions such as lifestyle modification, Ayurvedic detoxifying and purifying therapies and Ayurvedic medicines containing plant, animal, or mineral-origin ingredients, he added.

University of Mysore Vice-Chancellor Prof. G. Hemantha Kumar, Assistant Director of Government Ayurvedic Research Centre Dr. Lakshminarayana Shenoy, Joint Secretary of Ayurveda Academy Dr. Prashanth Ghokale, Junior pontiff of Ganapathy Ashram Datta Vijayananda Theertha Swamiji and others were present.

ABOUT

Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 41 years, Star of Mysore has been the newspaper that Mysureans reach for every evening to know about the happenings in Mysuru city. The newspaper has feature rich articles and dedicated pages targeted at readers across the demographic spectrum of Mysuru city. With a readership of over 2,50,000 Star of Mysore has been the best connection between it’s readers and their leaders; between advertisers and customers; between Mysuru and Mysureans.

CONTACT

Academy News Papers Private Limited, Publishers, Star of Mysore & Mysuru Mithra, 15-C, Industrial ‘A’ Layout, Bannimantap, Mysuru-570015. Phone no. – 0821 249 6520

To advertise on Star of Mysore, email us at

Print Editon: [email protected]
For News/Press Release: [email protected]

In what areas have the medical uses of traditional Indian medicine been studied?

Madhavbaug delivers evidence‑based Ayurveda therapies for cardiac ailments via virtual clinics, telemedicine, and digital partnerships.

Title:

Content: RaphaCure partners with Madhavbaug to enhance access to Cardiac Healthcare Services in India

RaphaCure company logo

Madhavbaug image

Cognota Healthcare Pvt. Ltd.

Madhavbaug is India’s leading cardiac care service provider leveraging the amalgamation of Ayurvedic treatments and modern medical science

We are excited to partner with RaphaCure for enhancing Madhavbaug’s digital healthcare solutions. This tie-up is a giant leap for making non-invasive care accessible for masses in remote regions.”
— Dr. Rohit Sane
BENGALURU, KARNATAKA, INDIA, January 24, 2022 /EINPresswire.com/ -- Leading digital healthcare services provider, RaphaCure on Monday said it has entered into a strategic partnership with Madhavbaug (Vaidya Sane Ayurved Laboratories Limited), India’s most prominent chain of clinics and hospitals in the cardiac care space leveraging the amalgamation of Ayurvedic treatments and modern medical science.

Madhavbaug (Vaidya Sane Ayurved Laboratories Limited) has a pan-India presence with a vast network of 272 clinics and two hospitals. With more than a decade of expertise in preventive cardiology, the healthcare company is a pioneer in non-invasive cardiac care in the world.

This strategic tie-up is a game-changing event for the cardiac care space wherein technology will be leveraged to reach out to patients even in the remotest regions of the country. RaphaCure and Madhavbaug will not only play to each other’s core strengths but will also tap their combined network for providing better patient care. Moreover, the partnership opens up new pathways for people to access ancient Ayurvedic Care which is India’s pride and heritage.

RaphaCure is powered by Cognota Healthcare, which is a leading healthtech company with multiple cutting-edge digital solutions. Together with RaphaCure, Cognota’s teleconsultation platform and Remote Patient Monitoring (RPM) solution is bringing in a paradigm shift in the Indian healthcare landscape. With this partnership with Madhavbaug, the duo will now bring the Indian system of medicine to patients’ doorsteps.

Commenting on this strategic collaboration, (Vaidya Sane Ayurved Laboratories Limited) Madhavbaug’s Founder, MD & CEO Dr. Rohit Sane said,” We are excited to partner with RaphaCure for enhancing Madhavbaug’s digital healthcare solutions. Recently in an event to inaugurate Madhavbaug Power MAP (a Digital Medical Analysis Application), Hon. Min. Shri Nitinji Gadkari encouraged Madhavbaug to extend chronic cardiac Healthcare solutions to low socio-economic classes and those living in remote areas through innovative technologies like Power MAP. This tie-up is a giant leap for making non-invasive care accessible for masses in the remote regions of the country through Raphacure-Cognota technology platform.”

Hailing the partnership as a breakthrough, Founder and MD of RaphaCure, Jeyakumar said, “As we move ahead, RaphaCure & Madhavbaug (Vaidya Sane Ayurved Laboratories Ltd) will complement each other in taking the path-breaking non-invasive cardiac care treatments to every nook and corner of the country. Leveraging our telemedicine platforms, Madhavbaug will expand its patient care reach further as we tap into each other’s network. With a great synergy in our operations and objectives, we will strive to take preventive cardiac care to the next level.”

Telemedicine adoption is growing at a rapid pace in India. A recent EY study estimates the market size to reach $5.5 billion by 2025.

“Indian healthcare ecosystem is digitalising at a rapid pace with telehealth seeing the highest adoption amid the pandemic. The collaboration between RaphaCure & Madhavbaug (Vaidya Sane Ayurved Laboratories Ltd) is a testimony to the fact that technology plays a crucial role in making this happen. As they leverage Cognota Healthcare’s multiple digital platforms to reach out to the remotest region of the country, we stay committed to integrating most advanced features that make this process seamless with utmost focus on client privacy and confidentiality,” said Sanjeev Dahiwadkar, Founder & CEO of Cognota Healthcare.

For more information contact us:

Tanvi Saha, Sr Manager- Client Relations
Cognota Healthcare Pvt Ltd.
Email: tanvi.s@cognotahealthcare.com
Contact: +91 8080447312
Linkedin

Madhavbaug (Vaidya Sane Ayurved Laboratories Ltd)
Dr. Suhas V. Dawkhar
Email: drsuhas@madhavbaug.com

Nanda Kumar
RaphaCure
+91 99676 48845
email us here

AYUSH QOL2C targets quality‑of‑life improvement for cancer patients through Ayurveda‑based adjuncts.

Title:

Content: India Cancer Treatment Drugs Market Huge Gains Projected for Market Over Next 7-Year Period

Quadintel offers a thorough analysis of the global “ India Cancer Treatment Drugs Market “, including assessments of business solutions, studies and advancements, applications, advantages, benefits, and breadth.

This market research study provides a thorough analysis and improvement of the important business producers, opportunities, difficulties, and worldwide suppliers as well as a close investigation of risks and access restrictions. Additionally, it provides a competitive analysis of the most recent technological advancements, innovations, future market potential, industry share, sales, sales generation, funding analysis, and overall business environment.

Download Free Sample of This Strategic Report :-https://www.quadintel.com/request-sample/india-cancer-treatment-drugs-market/16-13-1050

Insights into the Market During the Forecast Period (from 2023 to 28), the India Cancer Treatment Drugs Market is anticipated to expand at a CAGR of approximately 12.2%. In India, the disease has emerged as a concern for public health, with an estimated 1.39 million cases expected in 2020. In the past, more than 0.8 million people died from cancer in India in 2019.

The National Institute of Cancer Prevention and Research estimates that one woman in India dies from cervical cancer every eight minutes. In India, one woman dies from breast cancer for every two newly diagnosed women. In addition, the country’s tobacco use is on the rise, resulting in an increase in tobacco-related cancer deaths.

Changes in eating habits, food adulteration, environmental changes, an increase in chemical factories, etc., all contribute to a steady rise in cancer cases. are the main considerations for heightening malignant growth cases in India. Aside from these, an increase in cancer patients has been caused by a sedentary lifestyle and an excessive intake of junk food over the past few years. Accordingly, the requirement for convenient determination and preventive consideration is flooding at an outstanding speed, prompting broad interests in Research and development, in this manner making way for medication producers to concoct more viable medications to address such acceleration in the country.

Since the developed markets are relatively saturated in this industry, India has also seen remarkable opportunities for venture capitalists and investors. Additionally, the Ayushman Bharat Scheme’s effective diagnosis and treatment of cancer as well as the All India Institute of Medical Sciences (AIIMS)’s growing focus on oncology are likely to boost drug sales for cancer treatment. In addition, the industry has been positively impacted by the ever-increasing demand for effective medicines and the ever-improving infrastructure for cancer care in recent years, which includes upgraded facilities for tertiary care.

Mostly in the states of Madhya Pradesh, Odisha, Assam, Uttarakhand, Himachal Pradesh, Haryana, Delhi, Maharashtra, and Karnataka, among others, where the incidence of lip, oral, breast, and cervical cancer accounts for the majority of the cases. Consequently, requiring these cancer-related medications and accelerating their production during the anticipated time frame.

Request full Report Description, TOC, Table of Figure, Chart, etc : –https://www.quadintel.com/request-sample/india-cancer-treatment-drugs-market/16-13-1050

Key driver:

Market Dynamics Numerous Programs Promoting Affordable and Effective Cancer Diagnosis and Treatment One of the main focuses of the Pradhan Mantri Jan Arogya Yojana is protecting beneficiaries from the devastating costs of cancer treatment. Screening for oral, breast, and cervical cancer, as well as other common non-communicable diseases, is one of the services provided by the Ayushman Bharat Health and Wellness Centers (AB-HWCs).

Similar to this, the Ministry of Chemicals and Fertilizers’ National Pharmaceutical Pricing Authority (NPPA) published a list of 390 non-scheduled anti-cancer medications in 2019 with MRP reductions of up to 87 percent. This activity helped 22 lakh malignant growth patients in the country and would save buyers about Rs. 800 crores per year. Indian pharmaceutical companies are currently on an acquisition binge after a decade of prudent and organic growth. Additionally, cancer medications appear to be their primary focus, which ultimately drives the pharmaceutical industry.

Possible Limitation:

Access to medications like trastuzumab, rituximab, and bortezomib has been restricted as a result of rising catastrophic spending, which is characterized by significant OPP (out-of-pocket) expenditure in the private health care system. This is because the private sector has demonstrated significantly higher expenditure levels.

The study, which was supported by the Global Challenges program of the University of Birmingham, the India Institute of the University of Birmingham, and the National Institute for Health Research (NIHR), found that, depending on the type of cancer, patients were required to pay out-of-pocket expenses ranging from 19,494 to 295,679 Indian Rupees (INR).

The burden for health products and services decreases as a result of OPP payments, which include cost-sharing, self-medication, and other direct patient-borne costs that are not fully covered by insurance. This may have a negative impact on the industry in the coming years.

Learning experience: Ayurveda-Based Malignant growth Drug and Treatments

The public authority has put forth various attempts to energize Ayurveda research and the advancement of disease treatments. The government-established independent Central Council for Research in Ayurvedic Sciences (CCRAS) has conducted research on cancer, worked on drug development, and documented medical procedures, including the creation of AYUSH QOL2C to improve the quality of life for people with the disease. As a result, pharmaceuticals based on Ayurveda are likely to offer competitive businesses lucrative opportunities in the coming years.

Download free sample of this report :-https://www.quadintel.com/request-sample/india-cancer-treatment-drugs-market/16-13-1050

Key Pattern:

Increasing the number of cancer tertiary care facilities in the country The Central Government is expanding the Tertiary Care of Cancer Scheme to increase the number of resources for tertiary cancer care. So far, the program has approved 19 State Cancer Institutes (SCIs) and 20 Tertiary Care Cancer Centers (TCCCs). Six institutions have been established in Sikkim, Uttar Pradesh, Gujarat, Bihar, Tamil Nadu, and Kerala up until this point. The 33 other institutes are developing in various stages. Therapies and medications are necessary for better care, so developing tertiary care is likely to shape the industry in the coming years.

Market Division

In light of Treatment Type,

Chemotherapy
Designated Treatment
Immunotherapy
Hormonal Treatment
Other Treatment Types

The Designated treatment portion achieved the biggest market development in the authentic period. It is primarily attributable to the advanced efficacy, higher survival rates, and enormous potential of targeted therapies to kill only malignant cells. Then again, the immunotherapy portion is supposed to enlist the quickest development during 2023-28.

This monstrous development is related with the escalation of the frequencies of disease in India and the absence of related clinical help with the country. In addition, India’s public reimbursement programs do not include costly cancer medicines because it is one of the health systems with the fewest resources. This could result in catastrophic expenditure risks. Systemic anticancer therapy must therefore be thoroughly evaluated before being included in national formularies.

Request full Report Description, TOC, Table of Figure, Chart, etc : –https://www.quadintel.com/request-sample/india-cancer-treatment-drugs-market/16-13-1050

Cytotoxic drugs, targeted drugs, hormonal drugs, and others made up the majority of the medicines with the highest priority. Deeply grounded cytotoxic medications, presented to worldwide conventional contest in the beyond 10-20 years, incorporate doxorubicin, cyclophosphamide, paclitaxel, carboplatin, methotrexate, cytarabine, capecitabine, fluorouracil, and gemcitabine.

Moreover, Nonexclusive Chemotherapy specialists are the most high-need malignant growth medications by Indian oncologists as they work with significant enhancements in endurance and are now remembered for WHO EML. Recent Developments in the India Cancer Treatment Drugs Market In August 2022, AstraZeneca India, a pharmaceutical company, announced that the Drugs Controller General of India had given the go-ahead to commercialize its medication for breast cancer treatment, Lynparza (Olaparib), as a monotherapy.

PHESGO was the first ever fixed-dose formulation in oncology to combine two monoclonal antibodies – Perjeta (pertuzumab) and Herceptin ( Lynparza is the solitary endorsed medication focusing on BRCA (Bosom Disease quality) changes in beginning phase bosom malignant growth.

Dostarlimab, a medicine made in a lab that acts as a surrogate for antibodies in the human body, was discovered to have the potential to be a “possible” cancer cure for one of the most deadly tumors in a small clinical trial conducted by Memorial Sloan Kettering Cancer Center in June 2022 for the first time in history.

Are you in need of additional assistance?

The purpose of the sample report is to familiarize you with the overall research content and layout.
If you use the report strategically, you might be able to make your operations even more efficient and make more money.
You can customize the report to fit your needs by adding additional segments and specific countries. This will give you an unrivaled competitive advantage in your sector.
Feel free to get in touch with one of our knowledgeable analysts if you want more information about the current market situation.

Highlight the Following Key Factors:

  • Business Description: a particular description of agency operations and enterprise departments.
  • Company Strategy: The analyst’s precis of the company’s commercial enterprise strategy.
  • SWOT Analysis: Detailed evaluation of the company’s strengths, weaknesses, opportunities, and threats.
  • Company History: The development of predominant occasions associated to the company.
  • Main merchandise and services: A listing of the company’s fundamental products, services, and brands.
  • Main Competitors: A listing of the company’s fundamental competitors.
  • Important places and subsidiaries: The company’s major places and subsidiaries’ listing and contact information.
  • Detailed economic ratios of the previous 5 years: The trendy monetary ratios come from the annual economic statements issued by means of agencies with a record of 5 years.

Request Full Report :-https://www.quadintel.com/request-sample/india-cancer-treatment-drugs-market/16-13-1050

About Quadintel:

We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Quadintel is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.

  • Robust, detailed segmentation
  • In-depth analysis in all geographies.
  • Detailed breakup in various segmentation.
  • Rigorous primary and secondary research

We will help you in finding the upcoming trends that will entitle you as a leader in the industry. We are here to work with you on your objective which will create an immense opportunity for your organization. Our priority is to provide high-level customer satisfaction by providing innovative reports that enable them to take a strategic decision and generate revenue. We update our database on a day-to-day basis to provide the latest reports. We assist our clients in understanding the emerging trends so that they can invest smartly and can make optimum utilization of resources available.

Get in Touch with Us:

Quadintel:
Email:sales@quadintel.com
Address: Office – 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website : https://www.quadintel.com/

Dr BRKR Government Ayurvedic Medical College is studying Ayurvedic management of mucormycosis.

Title:

Content: Harish Rao announces plans to boost Ayurvedic medicine in Telangana

In an effort to establish Telangana as a hub for ayurvedic medicine, the government is investing Rs 10 crore in developing the Nature Cure Hospital in Begumpet.

Published: 26th June 2023 08:22 AM  |   Last Updated: 26th June 2023 08:22 AM   |  A+A-

By Express News Service

HYDERABAD: Health Minister T Harish Rao announced that significant measures would be taken to enhance the practice of ayurvedic medicine in the State. Speaking at a meeting organised for recently appointed ayurvedic doctors as Mid-Level Health Professionals (MLHPs) in rural dispensaries on Sunday, the minister revealed plans to construct new 50-bed Ayush hospitals in Vikarabad, Jayashankar Bhupalpally and Siddipet districts. The government intends to expand this initiative to encompass all districts across the State.

Additionally, a government centre will be built on 150 acres of land adjacent to the Jindal Ayurveda Hospital in Ananthagiri Hills, while the ayurveda hospital in Siddipet will be linked to the district’s medical college. A total of 3,071 candidates have received training as MLHPs, with one-third of them (1,154 individuals) being Ayurvedic doctors.

In an effort to establish Telangana as a hub for ayurvedic medicine, the government is investing Rs 10 crore in developing the Nature Cure Hospital in Begumpet. Currently, the State has 834 Ayush dispensaries, five colleges, and four research hospitals. Moreover, the government is actively working towards providing ayurvedic and unani treatments to neighbouring States, he added.

Addressing the ayurvedic doctors, Minister Harish expressed his appreciation for their valuable service to the State, particularly during the pandemic. He said that a significant role was played by four Ayush hospitals in the State in providing specialised services as quarantine centres.

The minister also commended the Dr BRKR Government Ayurvedic Medical College’s team for their research efforts in discovering a treatment for black fungus when there was a global shortage of medicine. Furthermore, he acknowledged the contributions made by Ayurveda doctors during the Kanti Velugu programme.

flipboard facebook twitter whatsapp

Institutions include the All India Institute of Ayurveda, National Institute of Unani Medicine, and Central Research Institute of Yoga & Naturopathy.

Title:

Content: Dibrugarh (Assam) [India], January 28 (ANI): Union Minister of Ports, Shipping & Waterways and Ayush, Shri Sarbananda Sonowal along with Assam Chief Minister Dr Himanta Biswa Sarma on Sunday laid the foundation stone of the Central Research Institute of Yoga & Naturopathy (CRIYN) along with a 100 bedded Yoga and Naturopathy hospital at Dihing Khamtighat in Dibrugarh.

The institution will be developed over a land parcel of nearly 15 acres (45 bighas) at an approximate investment of Rs 100 crore, with an aim at bringing a scientifically valid and useful synergy between traditional knowledge of Yoga and Naturopathy and modern tools of technology.

Also Read | Lok Sabha Speaker Om Birla Says Committee To Be Formed Under Maharashtra Assembly Speaker Rahul Narwekar To Review Country's Anti-Defection Law.

It will establish benchmark standards in education, Preventive healthcare and research in the field of Yoga and Naturopathy. This state-of-the-art institute will focus on fundamental aspects, scientific validation of traditional systems of medicine and practices through evidence based research, apart from functioning as an international collaboration centre for global promotion and research in Yoga and Naturopathy.

The institute will also serve as incubation centres in startups in the field of Yoga and wellness sector.

Also Read | Thane Shocker: Three-and-Half-Year-Old Missing Boy Found Dead in Residential Building's Water Tank in Bhiwandi, Probe Underway.

Speaking on the occasion, the Union Minister of Ports, Shipping & Waterways and Ayush, Sarbananda Sonowal, said, "Under the visionary leadership of Prime Minister Narendra Modi ji, the Ayush movement has got a tremendous boost as it has become a pioneering force of global wellness movement. Modiji's unrelenting focus to power India's growth engine with Northeast as powerhouse is resulting unprecedented growth. Today, we lay the foundation stone for the first of its kind Central Research Institute of Yoga & Naturopathy with a 100 bedded hospital in Dibrugarh. This is yet another testament of Modiji to empower Assam and the whole of Northeast to harness its rich flora & fauna and drive expansion in Ayush sector, with peripheral growth in hospitality, patient care as well as medical tourism sectors as well. Mother Nature has blessed us with her immense beauty and this will go a long way in providing a healing touch for people, of not just the immediate region but the South Asia region, with the rejuvenated, scientifically validated treatment regime through Yoga, Naturopathy, Ayurveda and other traditional forms of medicine."

"The institution will also offer clinical training facilities to train Yoga and Naturopathy experts for capacity building programs in areas of cardiac rehabilitation, Diabetes Rehabilitation, autoimmune diseases and NCD risk reduction," he added.

Sarbananda Sonowal also said that, with research and development in the protocols of Yoga and Naturopathy, CRIYN will develop evidence based protocols for management of NCDs that can be integrated with conventional care, reinforcing the Integrated Medicine approach of patient care.

The hospital will provide for inpatient services with Yoga and naturopathy protocols to heal and enrich quality of lives.

On this occassion Sarbananda Sonowal talked about Atmanirbhar Bharat stating, Modiji makes it a point to empower, enable and energise Northeast as the Powerhouse of India's economic growth, we stand at the threshold of an opportunity to seize the moment as India cruise towards becoming an Atmanirbhar Bharat.

Adding further, Sarbananda Sonowal said, "Dibrugarh has an illustrious history as the nerve centre of this region. Endowed with natural resources, it has always proved as a major driver of growth. Under the inspiring leadership of Prime Minister Narendra Modi ji, this growth saga has gained momentum since 2014. The resurgence of Ayush at the forefront of global wellness movement not only provides an economic rationale for India, but, more importantly, it is the virtuous and apt direction towards building a Swastha Bharat - a vision of Modiji. Today's initiative is a strong step towards realisation of this beautiful vision."

The event was also graced by the Union Minister of State Rameswar Teli, the Minister of Health & Family Welfare of Assam, Keshab Mahanta, the Minister of Industries & Commerce and Culture, Bimal Borah; the MLA of Dibrugarh and Chairman, Assam Industrial Development Council (AIDC), Prasanta Phukan; MLA of Moran, Chakradhar Gogoi, MLA of Duliajan, Terash Gowalla; MLA of Lahowal, Binod Hazarika; MLA of Chabua, Ponakan Baruah; MLA of Naharkatia, Taranga Gogoi among other dignitaries including senior officials of the Ministry of Ayush as well as Government of Assam.

"The centre will provide inpatient, outpatient, and day care services. The services offered by the centre are naturopathy diet and nutrition, yoga therapy, massage & manipulative therapies, acupressure, acupuncture, chromotherapy, magneto therapy, physiotherapy and hydrotherapy treatments," Sarbananda Sonowal said.

"It will help patients to effectively manage Obesity, Metabolic syndrome, diabetes, CVD, stroke, Asthma, COPD, Migraine, IBS, IBD, Arthritis, Autoimmune diseases, cancer, neurodegenerative diseases," he added.(ANI)

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)

A 100‑bed Yoga and Naturopathy hospital is planned at Dihing Khamtighat.

Amrita Center and the National Medicinal Plant Board map and research medicinal plant resources.

Title:

Content: Govt to document medicinal herbs of tribal communities

Centre to document medicinal herbs of tribal communities across country

The union ministry of tribal affairs carried out the initiative in Kerala, Rajasthan, Maharashtra as well as in Uttarakhand

The Centre is working on documenting medicinal herbs and healers of the tribal communities across the country. A pilot from Uttarakhand has been completed, resulting in a five-volume book series of over 1,400 medicinal plants. The exercise, officials said, will be carried out in more states.

The union ministry of tribal affairs carried out the initiative in Kerala, Rajasthan, Maharashtra as well as in Uttarakhand. Apart from documenting the plant and healers, they also documented the Sanskrit names of these plants.

In Kerala, the Amrita Vishwa Vidyapeetham was given the responsibility, All India Institute of Medical Studies Jodhpur in Rajasthan, Pravara Institute of Medical Sciences Ahmedabad for Maharashtra, and Patanjali carried it out in Uttarakhand.

While the others are carrying it out, Patanjali’s series of seven tomes are ready. In the hill state three districts were chosen, which included Pithoragarh and Udham Singh Nagar, all phytodiversity was documented by a team of over 50-50 people over a period of two years.

When asked about the Sanskrit nomenclature, the official said that it was a way of directing attention to the functionality of the plant.

“The National Medicinal Plant Board says there are over 1,500 plants in Uttarakhand, many of which are not even documented. But in three districts alone, we found 900 plants,” a senior official of the ministry said. “Tribal medicine holds considerable interest among researchers.”

Chemical analysis of all these plants was carried out, to find the active ingredient in the plant, with the help of an HPLC machine, officials said. Apart from that, samples of these were preserved, along with data on their therapeutic use. The official said that permissions from the biodiversity board were also taken.

In addition to that, the Hyderabad-based National Institute of Pharmaceutical Education and Research (NIPER) carried out a similar exercise in their areas where they found three medicinal plants, which when combined can be a cure for malaria. A similar exercise was carried out by the same team in the Rashtrapati Bhawan as well.

Healers in tribal communities in the areas that use these plants were also documented, along with data of their areas of expertise. In all, 750 healers were documented.

Officials said that after the successful pilot, the ministry has sent it to the AYUSH ministry, urging them to take it further across the country using SC/ST components from their funds. Officials also said that details of these plants will be put up online.

Check out DH's latest videos

Check out DH's latest videos

Get a round-up of the day's top stories in your inbox

Check out all newsletters

Get a round-up of the day's top stories in your inbox

India has a regulatory pathway for phytopharmaceuticals requiring evidence of quality, safety, and efficacy.

Title:

Content: Explainers
NEWS
12 hours ago

Does India Have Patience, Will And Resources To Build World's Top Cannabis Medicine Industry?

Raghav PriyadarshiUpdated on Mar 27, 2022, 16:03 IST

Consider the size of the opportunity — today’s billion dollar global medical cannabis industry is expected to hit USD 100 billion by 2028. That’s a 100x growth in the next six years.

We’ve missed the bus once — India is the largest producer and exporter of licit opium in the world, contributing over 50% of global volumes. Yet there is not a single Indian firm that is a global leader in manufacturing opioid medications, a USD 40 billion market annually!

Unspash/Representational image

On the back of successful medical cannabis regimes in countries such as Canada, Germany and increasingly the United States, hundreds of thousands of patients are able to access medical cannabis to treat a host of chronic conditions, most of which do not have safe or effective treatment pathways – neuropathic pains such as sciatica, fibromyalgia, and cancer-related pains; rheumatic conditions such as arthritis and multiple sclerosis; neurological conditions such as insomnia, migraine and Parkinson’s; or the ever increasing burden of mental health issues such as anxiety and depression – all conditions in which cannabinoid medicine has demonstrated ground-breaking results.

In this scenario, it is important to remember and highlight that India has the oldest medical cannabis regime in the world – in the form of Ayurveda – which records over 200 classical cannabis-based formulations. While Ayurveda recognises cannabis as a medicinal plant, allopathy does not.

Thus, modern formulations containing cannabis compounds cannot be manufactured and marketed with approvals from India’s drug regulator, until clinical research establishes the safety and efficacy of cannabis compounds in treating any particular condition. The onus is thus on the Indian pharmaceutical industry to undertake the required research to establish cannabinoids as therapeutic agents.

Unsplash/Representational image

Plant-derived drugs have tremendous potential, and the global pharma industry has barely scratched the surface of developing modern therapeutic formulations from medicinal plants. A case in point is ‘Artemisinin’, first extracted from Sweet Wormwood by Tu Youyou, a Chinese chemist who was awarded the Nobel Prize for Medicine in 2015 for demonstrating the efficacy of Artemisinin in treating malaria.

Tu Youyou drew inspiration from Traditional Chinese Medicine texts to find a cure for malaria, texts which prescribed using Sweet Wormwood to treat various fevers. Similarly, India too enjoys a unique position to build on the thousands of years of traditional medical knowledge contained in Ayurveda, to create novel therapeutics for unmet medical needs of the 21st century.

Cannabinoid medicine is projected to be the fastest growing life-sciences sector over the coming decade. Tapping this opportunity requires a change in mindset of Indian pharma, graduating from generic medicine manufacturing to R&D-based novel drug development. India has the necessary ecosystem – scientists, clinicians, researchers, a large drug manufacturing ecosystem and very large patient population – to really catapult the Indian life-sciences industry, and in particular cannabinoid therapeutics firms into global leaders.

Unsplash/Representational image

Cannabinoids have the potential to capture a significant share of this market with safer and effective alternatives to opioids and other analgesic medicines. The Indian drugs regulator has even issued regulations for a new class of plant-based drugs – ‘phytopharmaceuticals’ – a perfect bridge between traditional medicine manufacturing and modern allopathy.

Yet, seven years after the establishment of this hybrid regulatory regime, the Indian pharmaceutical industry is yet to respond with novel formulations registered under this category of medicine. It is high time we change our mindset, focus on value-added drug development, play by the rules of global pharma with respect to quality, safety and efficacy standards, and win!

The author is the founder and Chief Executive Officer of Savikalpa Sciences, a cannabinoid-focussed pharmaceutical firm. The views expressed in the article are author's own.

The Ayush Ministry warns manufacturers against misleading claims and enforces labeling and advertising norms.

Title:

Content: Active Stocks
Fri Apr 26 2024 15:54:22
  1. Tata Steel share price
  2. 165.85 -1.04%
  1. Kotak Mahindra Bank share price
  2. 1,608.40 -2.11%
  1. Wipro share price
  2. 464.65 0.79%
  1. ITC share price
  2. 439.95 0.56%
  1. Tech Mahindra share price
  2. 1,277.45 7.34%
Business News/ News / India/  'Misleading claim will attract...': Ayush ministry warns ayurvedic drugmakers after Patanjali's ads debacle
Back

'Misleading claim will attract...': Ayush ministry warns ayurvedic drugmakers after Patanjali's ads debacle

An advisory, reportedly issued by the Ayush ministry, issued a warning related to products that make unsubstantiate claims or display false information, such as featuring a green logo.

The Ministry of Ayush reportedly issued a warning to all Ayurvedic, siddha, unani, and homoeopathic drugmakers after the Supreme Court pulled up Patanjali Ayurved Ltd in connection with a misleading advertisements case.

According to News 18, the Ayushi ministry issued the warning, asking the drugmakers to "strictly comply with labelling and advertising regulations". Failing to adhere to regulations may attract legal action, the report added.

The clarification by the ministry was accessed by News 18, the report said, adding that the warning was related to products that make "unsubstantiated" claims or display false information, such as featuring a “green logo" claiming to be “100% vegetarian" or falsely stating that the drug is “approved or certified by the ministry".

ALSO READ: Patanjali in court: SC pulls up company, warns FMCG firms against misleading ads

Any misleading claim or advertisement in any form or on any platform will attract consequent legal actions by the competent authorities," the advisory was cited by News 18. The advisory also mentioned details about all laws and rules that cover misleading advertisements in the country.

The ministry reportedly ordered state drug licensing officials to examine all such drugs claiming to be “certified or approved by Ministry of Ayush" – either on their labels or in the advertisements. It further asked the officials to ensure compliance.

ALSO READ: Patanjali pulled up by the SC: Truth matters in advertising

'Ayush ministry has no role in granting manufacturing licences'

The advisory said licensing by the state drug licensing authority “shouldn’t be construed as an approval by the Ministry of Ayush", the report added.

“It has come to the notice of the Ministry of Ayush that some Ayush drug manufacturers are mentioning 'certified or approved by Ministry of Ayush' on the label of their drug or product or in the advertisement in print, electronic media,' the notice reportedly read.

ALSO READ: Patanjali ads cast a long shadow over FMCG sector

News 18 further reported that the ministry clarified it has no role in granting manufacturing licences or approvals to any Ayush drug or product.

It even cautioned that going forward, any such claim on the label or advertisement will attract “consequent legal action against the alleged manufacturer by the Ministry of Ayush".

ALSO READ: 'Apology only after...': Supreme Court rejects Ramdev's apology in Patanjali misleading ad case

The advisory further added the licence issued by a state authority is only permission to manufacture or sell a particular drug or product based on the fulfilment of conditions under the Drugs and Cosmetics Act, 1940.

The advisory was also sent to the National Pharmacovigilance Coordination Centre, which monitors and designs drug safety profiles, including the release of alerts, in case any drug is reporting new side effects.

ALSO READ: Baba Ramdev, Acharya Balkrishna tender unconditional apology for misleading Patanjali ads

According to News 18, the Centre was asked to “ensure reporting of such claims of approval or certification by Ministry of Ayush to concerned State Licensing Authority, under intimation to this Ministry of Ayush".

The warning came after Yoga guru Ramdev and his aide Balkrishna of Patanjali Ayurved Ltd tendered an "unconditional and unqualified apology" before the Supreme Court over advertisements issued by the firm making tall claims about the medicinal efficacy of its products.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 27 Apr 2024, 06:58 PM IST
Next Story
Recommended For You

Quality reforms include revised GMP, risk‑based inspections, and a digital regulatory ecosystem.

Title:

Content: World News
India orders new standards for pharmaceutical manufacturing
ABU DHABI (Reuters) - India ’ s pharmaceutical companies must set new manufacturing standards this year, according to a government notice issued on Saturday.
The notice, dated December 28, states: “The manufacturer must take responsibility for the quality of the products to ensure they are suitable for their intended use, comply with licensing requirements and do not put patients at risk. ”
The notification added that companies must market the finished product after achieving “satisfactory results ” in testing the ingredients.
India ’ s health ministry said in August that inspections at 162 pharmaceutical plants since December 2022 had revealed a “lack of testing for incoming raw materials. ”
Fewer than a quarter of India ’ s 8,500 small pharmaceutical factories comply with international standards for the manufacture of medicines set by the World Health Organization (WHO), the ministry said.
The notification stated that these concerns should be addressed by major pharmaceutical companies within six months and by small manufacturers within 12 months.
Advertisements
You may also read.

The government funded stronger drug regulation to reduce substandard medicines.

Title:

Content: In India, of the nearly 89,000 drug samples tested, more than 2,500 failed to meet the standards.
Such data was presented by the Minister of health of the country Mansuh Mandavia, reports Reuters.
About 380 samples were found to be fakes.
The government of India has allocated about $80 million to the Ministry of Health to strengthen the drug regulatory system, including the creation of laboratories for testing new drugs and the modernization of existing ones.
Over the past 10 years, exports of pharmaceuticals from India more than doubled to $24.5 billion in 2021-2022.
However, the deaths of 20 children in Uzbekistan and 200 in the Gambia and Indonesia after taking children's antipyretic syrups from Indian companies, in which ethylene glycol was found, undermined India's image as a "world pharmacy," the newspaper notes.
Last week, the Indian manufacturer Global Pharma Healthcare was also forced to withdraw all batches of its eye drops, as the United States registered 55 cases of side effects associated with taking the drug, including eye infections, irreversible loss of vision and one death, writes The Hindu BusinessLine.
At the end of January, the World Health Organization called on drug manufacturers to strengthen quality control of raw materials and the manufacturing process.
Governments should enact laws to combat substandard and falsified medicines and strengthen market surveillance, including informal surveillance.